Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults

NCT02753946 is registered in ClinicalTrials.gov with Nabriva Therapeutics AG as lead sponsor.

NCT NCT02753946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02753946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults
Lead sponsor
Nabriva Therapeutics AG
Phase
Phase 2/3
Overall status
Completed
Start date
April 30, 2016
Completion date
May 30, 2017
Enrollment
465 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, urinary tract infection complicated, urinary tract infection symptomatic